+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05587205

Phase 1 Study to Evaluate Safety and Tolerability of EO2002 Injection in Adults Undergoing Cataract Surgery

Led by Asociación para Evitar la Ceguera en México · Updated on 2025-12-08

32

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of EO2002, a biological treatment consisting of magnetic human corneal endothelial cells, in people who have undergone cataract surgery. This Phase 1 clinical trial focuses on subjects with cataract and decreased endothelial cell count, aiming to understand how EO2002 affects these patients post-surgery. The study is randomized, double-masked, and sham-controlled to carefully assess the treatments safety profile. Participants will receive a single dose of EO2002 injected into the eye either at the time of cataract surgery or after the surgery. There are multiple study groups including EO2002 given at surgery, EO2002 given after surgery, EO2002 given at or after surgery, and a sham injection group for comparison. The study is designed to closely monitor and compare these different treatment timings. During the study, participants will be followed for 26 weeks to assess safety and tolerability, including changes in endothelial cell density. Various eye examinations and assessments will be conducted regularly to monitor the treatment effects and any side effects. The study aims to provide detailed information on the safety of EO2002 in this patient population over a six-month period.

CONDITIONS

Brief Title

Safety and Tolerability of EO2002

Research Team

Y

Yara Luna

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here